REFRACTORY MANTLE CELL LYMPHOMA

This early-phase trial is testing whether combining two targeted drugs (pacritinib and a BTK inhibitor) is safe and effective for people with mantle cell lymphoma that has come back or stopped responding to prior therapy. The study will enroll 10 adults and monitor side effects a…

This early-stage trial tests two oral drugs, zanubrutinib and sonrotoclax, for people with B-cell non-Hodgkin lymphoma that has returned or not responded to prior treatment. The study focuses on Black, Hispanic, and other underrepresented groups to improve access and outcomes. Ab…

This study tests a drug called loncastuximab tesirine given after a short course of chemotherapy for people with mantle cell lymphoma that has returned or not responded to previous treatments, including BTK inhibitors. About 49 adults aged 18 to 84 will take part. The goal is to …

This study tests two drugs, glofitamab and obinutuzumab, in 20 adults with mantle cell lymphoma that came back or didn't respond after CAR T-cell therapy. Glofitamab helps the immune system attack cancer cells, while obinutuzumab blocks cancer growth. The goal is to see if this c…

This study tests whether a very low dose of radiation, given before or after drug therapy, can help control mantle cell lymphoma that has returned or stopped responding to treatment. About 80 adults will receive ultra low dose radiation to shrink tumors, aiming to improve respons…

This early-phase study tests a new treatment called MC10029, which uses a patient's own immune cells (T cells) that are modified in a lab to recognize and attack cancer cells. The therapy targets a protein called BAFFR found on certain blood cancer cells. The study includes up to…

This study tests a new treatment for mantle cell lymphoma that has returned or stopped responding to standard care. It combines a patient's own genetically modified immune cells (CAR-T cells) with a targeted drug (acalabrutinib) to attack cancer cells. The goal is to see if this …

This study tests a faster way to increase the dose of sonrotoclax, a drug that blocks a protein helping cancer cells survive. It is given after initial treatment with zanubrutinib or rituximab. The trial includes 30 adults with chronic lymphocytic leukemia, small lymphocytic lymp…

This phase 2 trial tests whether loncastuximab tesirine can shrink tumors in 20 adults with B-cell lymphomas that have returned or not responded to prior treatment. The drug is a targeted therapy that attaches to a protein on cancer cells and delivers a chemotherapy agent directl…